Screening for p53 mutations in exons 5 to 8 in 124 pediatric malignancies identi®ed 18 abnormal shifts using single strand conformation polymorphism: 12 were missense mutations and in 6, no mutation was detected in the exon or in the splice donor acceptor sequences. Sequencing was then performed in the adjacent introns, revealing a G to A base substitution at 39 base pairs upstream to exon 7. This mutation was identi®ed in the germ line of ®ve of the patients, and also in the father of one, whose parents were available. For comparison, of the 184 normal controls similarly screened, only one had this mutation (P=0.036). Positive staining of p53 protein was observed in three of the paran embedded tissues that were available: brain tumor, rhabdomyosarcoma, and lymphocytes from a normal lymph node from the rhabdomyosarcoma patient. All tumors with the identi®ed intron mutation were Li-Fraumeni syndrome tumors. Sequencing of all exons including splice sites was performed and revealed no mutation. We suggest that this mutation in intron 6 of the p53 gene stabilizes the wild type p53 protein, resulting in its abnormal accumulation. Mutations in the noncoding region of p53 should be further studied.
Introduction
Mutations in adult human cancer commonly involve the p53 suppressor gene, though in children, it is rarely aected. Its biological activity indicates that the protein is involved in gene transcription, DNA synthesis and repair, genome plasticity and apoptosis. The majority of somatic mutations in the p53 gene, especially missense, are clustered between exons 5 to 8, which are highly conserved (Greenblatt et al., 1994) . Germ line p53 mutations have been identi®ed in a familial form of cancer in which aected relatives develop a diverse set of early onset malignancies (sarcomas, breast carcinoma, brain tumors) termed Li-Fraumeni syndrome (LFS) (Li et al., 1988; Malkin et al., 1990; Srivastava et al., 1990) . They have also been identi®ed in patients with multiple primary cancers (Malkin et al., 1992; Toguchida et al., 1992) and in patients with a strong familial history of cancer aecting multiple tissues that does not meet the criteria for LFS (Metzger et al., 1991; Brugieres et al., 1993) . Many of these mutations are not unique and have been observed in sporadic tumors. The majority are missense mutations (Law et al., 1991; Birch et al., 1994; Frebourg et al., 1995) , though base substitution in splice-donor or spliceacceptor regions and nonsense mutations have been reported as well (Warneford et al., 1992; Felix et al., 1993; Jolly et al., 1994; Frebourg et al., 1995) . A germ line deletion causing loss of the entire p53 oligomerization domain has also been identi®ed (Plummer et al., 1994) . Recently, a new germ line transmission, a replication error was identi®ed in a LFS family (Strauss et al., 1995) . Most of the germ line mutations have been shown to be inherited, and only 2 of 18 were shown to be de novo .
We have identi®ed a novel germ line p53 mutation in intron 6 in six pediatric patients with diverse tumors, all belong to the Li-Fraumeni syndrome. High p53 protein expression was identi®ed by immunohistochemistry in the two available tumors and in one available normal lymph node. We suggest that this mutation stabilizes the p53 protein, causing an abnormal accumulation that predisposes the individual to cancer. Intronic sequences of p53 should be determined.
Results
Screening for p53 mutations in exons 5 to 8 identi®ed 18 abnormal shifts, and subsequent sequencing analysis detected 12 missense mutations: six in exon 5, three in exon 7 and three in exon 8 (manuscripts in preparation). In the remaining six patients described in Table 1 , the abnormal shift in exon 7 (Figure 1 ) was not associated with a mutation of the exon or the splicing junctions. In ALL patient no. 4, a second abnormal shift was observed in exon 5 which had proved as a missense mutation in codon 132 in all Correspondence: S Avigad Received 8 July 1996; revised 6 December 1996; accepted 9 December 1996 
PBL: peripheral blood leukocytes; Brain: medulloblastoma; RMS: rhabdomyosarcoma; ALL: acute lymphoblastic leukemia; +: harbored the intronic mutation; ±: did not harbor the intronic mutation; n.d.: not done relapse samples (data not shown, paper submitted). Since the identical abnormal shifts were observed in quite a number of patients with diverse tumors, we sequenced the¯anking introns for any base substitution that could explain them. The primers we have designed for exon 7 are 58 and 61 bases upstream and downstream, respectively, from exon 7, so we sequenced from primer to primer.
A base substitution (G to A) was identi®ed at 39 base pairs upstream to exon 7 (Figure 2 ) in all six patients in Table 1 . This change was also identi®ed in the normal tissue of ®ve of the six patients and in one of the parents (Figure 3) .
Thereafter, to determine whether this change is a rare polymorphism, we screened exon 7 of the p53 gene by SSCP analysis (using the same primers) in 184 healthy controls. In one of them, the same abnormal shift was detected (not shown). The dierence in the rate of this mutation between the patients and the healthy controls was signi®cant by Yates corrected chi square test (w 2 =4.36, P=0.036). Encouraged by this ®nding, we checked if this change could have resulted in an alternative splice site. Total RNA was extracted from one of the RMS patients (no. 2), from one of the ALL patients (no. 6) and from a healthy control. RT-PCR was performed for the cDNA fragment containing exons 5 to 10 (623 bp) and for the cDNA of the bglobin (240 bp) as a normal control. No change in size of the mRNA was detected, nor was it increased compared to the internal control (data not shown).
Immunohistochemistry study was performed on paran embedded tissues from patient no. 1 (brain tumor) and patient no. 2 (rhabdomyosarcoma tumor and normal lymph node); an increase in the amount of p53 protein was noted in all tissues (Figure 4) .
We extended the direct sequencing to all exons and splice junctions of the p53 gene and revealed no additional mutation.
Figure 1 SSCP analysis of exon 7 of the p53 gene. Abnormal shift is identi®ed in ALL patients: patient no. 4 in all samples except R2 and R3 (due to LOH of this allele during progression) and patient no. 6 in all samples, as compared to the negative control (C). AD: at diagnosis; R1: ®rst relapse; R2: second relapse; R3: third relapse; RM: remission Figure 2 Sequence analysis of intron 6 of the p53 gene. Base substitution of C to T at 39 base pairs upstream to exon 7 is identi®ed in the normal PBL and medulloblastoma tumor of patient no. 1. The control is a PBL of a healthy individual 
Discussion
We have identi®ed a novel germ line base substitution in intron 6 of the p53 gene in six pediatric malignancies. No additional mutation was identi®ed in the coding region using direct sequencing analysis. Interestingly, positive staining of p53 protein was observed in two tumors and in one normal lymph node, that were available. There was a signi®cant dierence in the rate of this substitution between patients and healthy controls. Based on our ®ndings, we suggest that the base substitution identi®ed in intron 6 of the p53 gene stabilizes the wild type p53 protein, resulting in its accumulation, which in turn, predisposes the individual to cancer. A similar result has been published by Barnes et al. (1992) , in a mother and daughter with breast cancer who had constitutively large quantities of p53 protein without any detectable p53 mutation in the whole coding region of the gene. They suggested that a germ line mutation outside the p53 coding region was aecting expression of the p53 protein. They, too, could not detect any dierence between the mRNA and the actin mRNA.
Introns are thought to have gene regulatory roles, leading to susceptibility to cancer (Malkinson and You, 1994) . A recent novel polymorphism in intron 6 has been reported (Peller et al., 1995) indicating a possible association with cancer predisposition and susceptibility. In our study, even if the substitution is a rare polymorphism, it is signi®cantly associated with a predisposition to cancer. In addition, another germ line intron 6 mutation has been identi®ed in our laboratory (manuscript submitted) in a three generation LiFraumeni syndrome family, also resulting in accumulation of the wild type p53 protein. These results may implicate intron 6 in the stabilization of the p53 protein. It is tempting to assume that intronic mutations, via other genes, may regulate the p53 protein.
Our mutation has been identi®ed in the germ line of ®ve of six patients (83%), and in somatic form in one RMS patient (no. 3). The same change was identi®ed in the father of patient no. 1 (Figure 3 ), but not in the father of patient no. 2 (mother not tested). Interestingly, the same mutation was identi®ed in three diverse types of malignancies; brain, RMS and ALL, all part of LFS. None of the Ewing Family of tumors (ETs) (30 patients), which are not part of the LFS, had this mutation.
The only family history known to us was of patient no. 4 where the ®rst degree cousin of the patient's mother had had carcinoma of the ovary at age of 29 and secondary leukemia at age of 37. This family had another son with a large nevus on the arm. In patient no. 2 with RMS and the germ line mutation in the intron, the disease was congenital.
To date, p53 mutations have been identi®ed in only 50% of LFS families. For the remaining 50%, we suggest that in some, mutations are bound to be identi®ed in the noncoding introns, altering the regulation of the protein.
We conclude, that mutations, especially germ line mutations, of the noncoding regions of the p53 gene are more frequent in childhood malignancies than anticipated.
Intronic mutations play a role in stabilizing the p53 wild type protein, resulting in its abnormal accumulation and predisposing the individual to cancer. Therefore, intronic sequences of p53 should be determined in childhood malignancies.
Materials and methods

Tumor samples
Analysis was performed in 124 pediatric tumors: 32 brain tumors, 30 Ewing family of tumors (ETs), 14 rhabdomyosarcoma (RMS), 11 osteosarcoma, and 37 acute lympho- blastic leukemia (ALL). Tumor tissues were frozen immediately after surgical removal and stored at 7708C until use. High molecular DNA was extracted using standard methods (Sambrook et al., 1989) .
Screening for mutations in the p53 gene
Screening was performed for exons 5 ± 8 by SSCP method (Orita et al., 1989) . Primer pairs were designed to amplify a fragment containing each exon. PCR fragments included the¯anking intron regions surrounding each exon. For SSCP analysis, an aliquote of 2 ± 3 ml ampli®ed product was diluted with 0.1% SDS; 10 mM EDTA mixture to ®nal volume of 10 ml, followed by 1 : 1 dilution with 95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylen cyanol loading solution. Diluted samples were heat denatured and then loaded on MDE (Hydrolink) gels (AT Biochem. Inc.). Electrophoresis was performed at 3 W for 13 ± 17 h at room temperature in a Hoeer device (SE-600). The gels were silver stained.
Sequencing
Sequencing was done by solid phase sequence analysis using streptavidin 280 (Dynals) and the Sanger's dideoxy method (Sequenase 2.0, USB kit). PCR fragments spanning exons 2 ± 4, 5 ± 9 and 10 ± 11 were ampli®ed using the following primers: sense 5'-CCACTTTTCCTCTTGC AGCAG -3', antisense 5'-CTCATGGAAGCCAG-CCGCTC-3', sense 5'-CAACTCTGTCTCCTTCCTCT-3', antisense 5'-TCAC-TGCCCCCTGATGGCAA-3' and sense 5'-CCATC-T-TTTAACTCAGGTAC-3', antisense 5'-ACA-GACCCTCTCACTCATGT-3', respectively. Nested primers were used for sequencing analysis. Electrophoresis was performed on 6% denaturing polyacrylamide gel. Autoradiography was carried out at room temperature.
Total RNA was extracted using the TRI reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's instructions. First strand cDNA was synthesized using superscript II RNase H-reverse transcriptase (Gibco BRL, Gaithersburg, MD) with random hexamers, for 1 h at 378C. RT-PCR was performed using primers for exons 5 to 10: sense 5'-GCTGTGGGTTGATTCCAC-3' and antisense 5'-CCTGGGCATCCTTGAGTT-3' resulting in a 623 bp fragment.
Immunohistochemistry
Five micrometers of paran-embedded tissue were cut and mounted on Silanprop slides (Sigma). Following deparanization in xylene and dehydration with graded ethanol, sections were transferred to a plastic coplin jar containing 0.1 mol/L sodium citrate (pH 6.0) and heated in a household microwave oven for 10 min at 928C. Treated slides were allowed to cool for a minimum of 15 min prior to processing for immunohistochemistry, as previously described (Fogel et al., 1990) . The primary anti-p53 antibody DO-1 (kindly provided by Dr V Rotter, Weizmann Institute, Rehovot, Israel) which identi®es wild type and mutant p53 protein, was used for staining.
